Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>Kim A. Reiss, Susan M. Domchek, Janae Romeo et al.|Journal of Clinical Oncology|2021Cited by 238
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutationMax M. Wattenberg, Kim A. Reiss, Daniella Asch et al.|British Journal of Cancer|2019Cited by 206
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer modelsPatrizia Porazzi, Marco Ruella, Siena Nason et al.|Cancer Cell|2025Cited by 47
Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancerYan Li, Gregory L. Beatty|Cell Reports Medicine|2024Cited by 24